• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新型嘌呤支架 Hsp90 抑制剂 PU-H71 对人肺癌细胞的放射增敏作用。

Radiosensitization of human lung cancer cells by the novel purine-scaffold Hsp90 inhibitor, PU-H71.

机构信息

Department of Radiological Sciences, Center for Humanity and Arts, Ibaraki Prefectural University of Health Sciences, Ami-machi, Inashiki-gun, Ibaraki 300-0394, Japan.

Department of Biology, Center for Humanity and Arts, Ibaraki Prefectural University of Health Sciences, Ami-machi, Inashiki-gun, Ibaraki 300-0394, Japan.

出版信息

Int J Mol Med. 2014 Mar;33(3):559-64. doi: 10.3892/ijmm.2013.1594. Epub 2013 Dec 19.

DOI:10.3892/ijmm.2013.1594
PMID:24366006
Abstract

The molecular chaperone heat shock protein 90 (Hsp90) is involved in the maturation and stabilization of a wide range of oncogenic client proteins for oncogenesis and malignant cell proliferation, which renders this protein a promising target in the development of cancer therapeutics. PU-H71 is a purine-scaffold Hsp90 inhibitor with less toxicity in normal cells than in cancer cells. In this study, we examined the in vitro radiosensitizing activity and molecular mechanisms of action of PU-H71 in human lung cancer cell lines. PU-H71 enhanced the sensitivity of the SQ-5 and A549 cancer cells to radiation. When the cancer cells were pre-treated with PU-H71, the repair of DNA double-strand breaks (DSBs) was markedly inhibited after irradiation compared with the cells that were not pre-treated with PU-H71, as evaluated by counting the foci of phosphorylated histone H2AX (γ-H2AX). We further demonstrated that post-irradiation, PU-H71 inhibited Rad51 foci formation, a critical protein for the homologous recombination pathway of DNA DSB repair. These data indicate that targeting Hsp90 with PU-H71 may be novel therapeutic strategy for radioresistant carcinomas.

摘要

热休克蛋白 90(Hsp90)是一种分子伴侣,参与多种致癌客户蛋白的成熟和稳定,从而促进肿瘤发生和恶性细胞增殖,这使得该蛋白成为癌症治疗开发中有前途的靶标。PU-H71 是一种嘌呤支架 Hsp90 抑制剂,在正常细胞中的毒性低于癌细胞。在这项研究中,我们研究了 PU-H71 在人肺癌细胞系中的体外放射增敏活性和作用机制。PU-H71 增强了 SQ-5 和 A549 癌细胞对辐射的敏感性。当用 PU-H71 预处理癌细胞时,与未用 PU-H71 预处理的细胞相比,辐射后 DNA 双链断裂(DSB)的修复明显受到抑制,通过检测磷酸化组蛋白 H2AX(γ-H2AX)的焦点来评估。我们进一步证明,照射后,PU-H71 抑制 Rad51 焦点形成,Rad51 焦点形成是 DNA DSB 修复同源重组途径的关键蛋白。这些数据表明,用 PU-H71 靶向 Hsp90 可能是治疗辐射抗性癌的新策略。

相似文献

1
Radiosensitization of human lung cancer cells by the novel purine-scaffold Hsp90 inhibitor, PU-H71.新型嘌呤支架 Hsp90 抑制剂 PU-H71 对人肺癌细胞的放射增敏作用。
Int J Mol Med. 2014 Mar;33(3):559-64. doi: 10.3892/ijmm.2013.1594. Epub 2013 Dec 19.
2
The purine scaffold Hsp90 inhibitor PU-H71 sensitizes cancer cells to heavy ion radiation by inhibiting DNA repair by homologous recombination and non-homologous end joining.嘌呤骨架热休克蛋白90抑制剂PU-H71通过抑制同源重组和非同源末端连接的DNA修复,使癌细胞对重离子辐射敏感。
Radiother Oncol. 2016 Oct;121(1):162-168. doi: 10.1016/j.radonc.2016.08.029. Epub 2016 Sep 22.
3
PU-H71, a novel Hsp90 inhibitor, as a potential cancer-specific sensitizer to carbon-ion beam therapy.新型热休克蛋白90(Hsp90)抑制剂PU-H71作为碳离子束治疗潜在的癌症特异性增敏剂。
J Radiat Res. 2016 Sep;57(5):572-575. doi: 10.1093/jrr/rrw054. Epub 2016 May 29.
4
Hsp90 inhibition by PU-H71 induces apoptosis through endoplasmic reticulum stress and mitochondrial pathway in cancer cells and overcomes the resistance conferred by Bcl-2.PU-H71对热休克蛋白90的抑制作用通过内质网应激和线粒体途径诱导癌细胞凋亡,并克服了Bcl-2所赋予的耐药性。
Biochim Biophys Acta. 2013 Jun;1833(6):1356-66. doi: 10.1016/j.bbamcr.2013.02.014. Epub 2013 Feb 26.
5
HSP90 inhibitor PU-H71 increases radiosensitivity of breast cancer cells metastasized to visceral organs and alters the levels of inflammatory mediators.HSP90 抑制剂 PU-H71 增加转移至内脏器官的乳腺癌细胞的放射敏感性,并改变炎症介质的水平。
Naunyn Schmiedebergs Arch Pharmacol. 2020 Feb;393(2):253-262. doi: 10.1007/s00210-019-01725-z. Epub 2019 Sep 14.
6
The anti-myeloma activity of a novel purine scaffold HSP90 inhibitor PU-H71 is via inhibition of both HSP90A and HSP90B1.新型嘌呤骨架 HSP90 抑制剂 PU-H71 的抗骨髓瘤活性是通过抑制 HSP90A 和 HSP90B1 实现的。
J Hematol Oncol. 2010 Oct 26;3:40. doi: 10.1186/1756-8722-3-40.
7
Prospective identification of resistance mechanisms to HSP90 inhibition in KRAS mutant cancer cells.KRAS 突变癌细胞中 HSP90 抑制耐药机制的前瞻性鉴定。
Oncotarget. 2017 Jan 31;8(5):7678-7690. doi: 10.18632/oncotarget.13841.
8
Pre-clinical efficacy of PU-H71, a novel HSP90 inhibitor, alone and in combination with bortezomib in Ewing sarcoma.新型 HSP90 抑制剂 PU-H71 单独及联合硼替佐米治疗尤文肉瘤的临床前疗效。
Mol Oncol. 2014 Mar;8(2):323-36. doi: 10.1016/j.molonc.2013.12.005. Epub 2013 Dec 15.
9
Radiosynthesis of the iodine-124 labeled Hsp90 inhibitor PU-H71.碘-124标记的热休克蛋白90抑制剂PU-H71的放射性合成
J Labelled Comp Radiopharm. 2016 Mar;59(3):129-32. doi: 10.1002/jlcr.3369. Epub 2016 Jan 25.
10
Targeting the Hsp90-associated viral oncoproteome in gammaherpesvirus-associated malignancies.靶向γ疱疹病毒相关恶性肿瘤中 HSP90 相关病毒癌蛋白组。
Blood. 2013 Oct 17;122(16):2837-47. doi: 10.1182/blood-2013-01-479972. Epub 2013 Aug 13.

引用本文的文献

1
PU-H71 (NSC 750424): a molecular masterpiece that targets HSP90 in cancer and beyond.PU-H71(NSC 750424):一种靶向癌症及其他领域中热休克蛋白90(HSP90)的分子杰作。
Front Pharmacol. 2024 Nov 5;15:1475998. doi: 10.3389/fphar.2024.1475998. eCollection 2024.
2
Ganetespib selectively sensitizes cancer cells for proximal and distal spread-out Bragg peak proton irradiation.甘替斯匹布选择性地使癌细胞对近端和远端展宽布拉格峰质子照射敏感。
Radiat Oncol. 2022 Apr 11;17(1):72. doi: 10.1186/s13014-022-02036-z.
3
SNX-2112 Induces Apoptosis and Inhibits Proliferation, Invasion, and Migration of Non-Small Cell Lung Cancer by Downregulating Epithelial-Mesenchymal Transition via the Wnt/β-Catenin Signaling Pathway.
SNX-2112通过Wnt/β-连环蛋白信号通路下调上皮-间质转化,从而诱导非小细胞肺癌细胞凋亡并抑制其增殖、侵袭和迁移。
J Cancer. 2021 Aug 3;12(19):5825-5837. doi: 10.7150/jca.56640. eCollection 2021.
4
Exploiting DNA repair pathways for tumor sensitization, mitigation of resistance, and normal tissue protection in radiotherapy.利用DNA修复途径实现肿瘤增敏、减轻放疗抗性以及保护正常组织。
Cancer Drug Resist. 2021;4(2):244-263. doi: 10.20517/cdr.2020.89. Epub 2021 Jun 19.
5
gene expression signature analysis revealed bosutinib as a radiosensitizer of breast cancer cells by targeting eIF4G1.基因表达谱分析显示,博舒替尼通过靶向 eIF4G1 成为乳腺癌细胞的放射增敏剂。
Int J Mol Med. 2021 May;47(5). doi: 10.3892/ijmm.2021.4905. Epub 2021 Mar 11.
6
Strategies to Enhance Radiosensitivity to Heavy Ion Radiation Therapy.增强重离子放射治疗放射敏感性的策略
Int J Part Ther. 2018 Summer;5(1):114-121. doi: 10.14338/IJPT-18-00014.1. Epub 2018 Sep 21.
7
HSP90 inhibitor PU-H71 increases radiosensitivity of breast cancer cells metastasized to visceral organs and alters the levels of inflammatory mediators.HSP90 抑制剂 PU-H71 增加转移至内脏器官的乳腺癌细胞的放射敏感性,并改变炎症介质的水平。
Naunyn Schmiedebergs Arch Pharmacol. 2020 Feb;393(2):253-262. doi: 10.1007/s00210-019-01725-z. Epub 2019 Sep 14.
8
Translational research in radiation-induced DNA damage signaling and repair.辐射诱导的DNA损伤信号传导与修复的转化研究。
Transl Cancer Res. 2017 Jul;6(Suppl 5):S875-S891. doi: 10.21037/tcr.2017.06.02.
9
First-in-human study of the epichaperome inhibitor PU-H71: clinical results and metabolic profile.人用首研 EPICHAPEROME 抑制剂 PU-H71:临床结果和代谢特征。
Invest New Drugs. 2018 Apr;36(2):230-239. doi: 10.1007/s10637-017-0495-3. Epub 2017 Aug 12.
10
Drugging the Cancers Addicted to DNA Repair.对依赖DNA修复的癌症进行药物治疗。
J Natl Cancer Inst. 2017 Nov 1;109(11). doi: 10.1093/jnci/djx059.